Open Access

lncRNA NORAD promotes the progression of osteosarcoma via targeting of miR‑155‑5p

  • Authors:
    • Ye Wang
    • Bin Zhou
    • Liping Yan
    • Jianhui Wu
    • Zhijie Xing
    • Shaochun Zhang
    • Fusheng Xiang
  • View Affiliations

  • Published online on: April 18, 2021     https://doi.org/10.3892/etm.2021.10077
  • Article Number: 645
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma (OS) is the most common malignant bone tumor in teens. Non‑coding RNA activated by DNA damage (NORAD), a long non‑coding RNA (lncRNA), has been reported to be involved in cancer biology, although its role in OS remains largely unknown. In the present study reverse transcription‑quantitative PCR (RT‑qPCR) was used to determine the expression levels of NORAD and miR‑155‑5p in samples from patients with OS. OS cell lines (Saos‑2 and U2OS) were used as cell models. The biological influence of NORAD on OS cells was studied in vitro using Cell Counting Kit‑8 and Transwell assays. The interaction between NORAD and miR‑155‑5p was clarified by bioinformatics analysis, RT‑qPCR, luciferase reporter assay and RNA immunoprecipitation. NORAD was significantly increased in OS samples in comparison with controls, while miR‑155‑5p was reduced. Knockdown of NORAD and transfection of miR‑155‑5p mimics markedly inhibited the viability, migration and invasion of OS cells. There was a negative correlation between NORAD and miR‑155‑5p expression levels in OS samples. Taken together, the results of the present study indicated that the NORAD/miR‑155‑5p axis played a crucial role in regulating the proliferation, migration and invasion of OS cells. It is hypothesized that NORAD and miR‑155‑5p may serve as potential novel therapeutic targets for OS management.

Related Articles

Journal Cover

June-2021
Volume 21 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Y, Zhou B, Yan L, Wu J, Xing Z, Zhang S and Xiang F: lncRNA NORAD promotes the progression of osteosarcoma via targeting of miR‑155‑5p. Exp Ther Med 21: 645, 2021
APA
Wang, Y., Zhou, B., Yan, L., Wu, J., Xing, Z., Zhang, S., & Xiang, F. (2021). lncRNA NORAD promotes the progression of osteosarcoma via targeting of miR‑155‑5p. Experimental and Therapeutic Medicine, 21, 645. https://doi.org/10.3892/etm.2021.10077
MLA
Wang, Y., Zhou, B., Yan, L., Wu, J., Xing, Z., Zhang, S., Xiang, F."lncRNA NORAD promotes the progression of osteosarcoma via targeting of miR‑155‑5p". Experimental and Therapeutic Medicine 21.6 (2021): 645.
Chicago
Wang, Y., Zhou, B., Yan, L., Wu, J., Xing, Z., Zhang, S., Xiang, F."lncRNA NORAD promotes the progression of osteosarcoma via targeting of miR‑155‑5p". Experimental and Therapeutic Medicine 21, no. 6 (2021): 645. https://doi.org/10.3892/etm.2021.10077